InvestSMART

Dimerix Limited (ASX: DXB) - Announcements

Current share price for DXB : $0.205 0.005 (2.38%)+

ASX company news and announcements for Dimerix Limited (DXB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Dimerix Limited (DXB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Dimerix Limited (DXB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Dimerix Limited (DXB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$123 Ausbiotech Conference Presentation 30 Oct 2019 9:36AM $0.110 $0.205 risen by 86.36%
$123 Notice of Annual General Meeting/Proxy Form 29 Oct 2019 8:58AM $0.110 $0.205 risen by 86.36%
$123 Quarterly Commentary & Appendix 4C 25 Oct 2019 8:58AM $0.105 $0.205 risen by 95.24%
$123 Dimerix Awarded Second Innovation Connections Grant 23 Oct 2019 9:29AM $0.105 $0.205 risen by 95.24%
$123 Final Director's Interest Notice 11 Oct 2019 8:34AM $0.115 $0.205 risen by 78.26%
$123 Director Resignation 11 Oct 2019 8:30AM $0.115 $0.205 risen by 78.26%
$123 New Drug Pipeline Candidate DMX-700 & Company Update 10 Oct 2019 8:32AM $0.115 $0.205 risen by 78.26%
$123 Receipt of R&D Tax Incentive 8 Oct 2019 9:29AM $0.105 $0.205 risen by 95.24%
$123 DMX-200 Phase 2 Clinical Study in DKD Completes Recruitment 26 Sep 2019 9:27AM $0.092 $0.205 risen by 122.83%
$123 Additional US Patent Covering DMX-200 17 Sep 2019 9:37AM $0.093 $0.205 risen by 120.43%
$123 Annual Report to shareholders 29 Aug 2019 10:20AM $0.100 $0.205 risen by 105%
$123 Appendix 4G and Corporate Governance Statement 29 Aug 2019 10:13AM $0.100 $0.205 risen by 105%
$123 Preliminary Final Report 29 Aug 2019 10:10AM $0.100 $0.205 risen by 105%
$123 Appendix 3B 9 Aug 2019 12:23PM $0.100 $0.205 risen by 105%
$123 Dimerix to Present at Bioshares Biotech Summit 2019 25 Jul 2019 9:46AM $0.105 $0.205 risen by 95.24%
$123 Quarterly Commentary & Appendix 4C 16 Jul 2019 9:31AM $0.100 $0.205 risen by 105%
$123 First DMX-200 Patents To Grant In Europe And Canada 11 Jul 2019 9:28AM $0.110 $0.205 risen by 86.36%
$123 DMX-200 Phase 2 Clinical Trial in FSGS Fully Recruited 10 Jul 2019 9:28AM $0.105 $0.205 risen by 95.24%
$123 Investor Presentation 26 Jun 2019 9:27AM $0.082 $0.205 risen by 150%
$123 DMX-200 Clinical Update 26 Jun 2019 9:23AM $0.082 $0.205 risen by 150%
$123 Dimerix Signs Licence Agreement for Receptor-HIT Technology 24 Jun 2019 9:38AM $0.074 $0.205 risen by 177.03%
$123 DMX-200 Manufacturing Update 27 May 2019 9:28AM $0.076 $0.205 risen by 169.74%
$123 CFO and Company Secretary Appointment/Resignation 6 May 2019 9:25AM $0.085 $0.205 risen by 141.18%
$123 Appendix 4C - quarterly 26 Apr 2019 12:10PM $0.089 $0.205 risen by 130.34%
$123 Appendix 3B 15 Mar 2019 6:59PM $0.086 $0.205 risen by 138.37%

526 - 550 of 746 results

Page 22 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.